COCP - Cocrystal Pharma, Inc. News

Cocrystal Pharma Secures $5M Investment From OPKO Health To Advance Norovirus Program Toward Phase 1

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b

Financial Contrast: Cocrystal Pharma (NASDAQ:COCP) vs. Zevra Therapeutics (NASDAQ:ZVRA)

Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cocrystal Pharma (NASDAQ: COCP - Get Free Re

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Devel

BOTHELL, Wash. , June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) ("Cocrystal"

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and In

Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

BOTHELL, Wash., May 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal”

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement o

BOTHELL, Wash., April 30, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal

12 Health Care Stocks Moving In Monday's Pre-Market Session

Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results

US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Q

12 Health Care Stocks Moving In Thursday's Intraday Session

Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988

The company said the FDA's Fast Track designation is intended to facilitate development and expedite

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment a

FDA Fast Track designation supports accelerated development and expedites regulatory review Noroviru

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Developme

Phase 1b norovirus challenge study is underway at Emory University School of Medicine CDI-988 is the

Cocrystal Pharma (COCP) Expected to Announce Earnings on Monday

Cocrystal Pharma (NASDAQ: COCP - Get Free Report) is anticipated to issue its results before the mar

Cocrystal Pharma (NASDAQ:COCP) Shares Up 2% – Should You Buy?

Cocrystal Pharma, Inc. (NASDAQ: COCP - Get Free Report)'s stock price traded up 2% during mid-day tr

First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Preventio

CDI-988 is a direct-acting, oral antiviral being developed for norovirus Norovirus challenge study i

Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the Internation

BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal”

Insider Buying: Cocrystal Pharma (NASDAQ:COCP) Director Buys $19,400.00 in Stock

Cocrystal Pharma, Inc. (NASDAQ: COCP - Get Free Report) Director Phillip Md Et Al Frost bought 20,00

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human C

BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal”

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference

BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal”

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral

Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatment Expects to

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nas

Investment by Directors and Management demonstrates confidence in the Company Potential for an addit

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

On Monday, 413 companies reached new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

On Friday morning, 446 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 838 companies hit new 52-week lows.

During Monday's trading, 528 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

On Friday, 404 stocks made new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 44 companies hit new 52-week lows.

Monday saw 825 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 1076 companies hit new 52-week lows.

On Monday, 429 stocks made new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

On Friday, 1043 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 729 companies set new 52-week lows.

35 Stocks Moving In Wednesday's Mid-Day Session